Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 10/20 | 0.74 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112510 | 0.85 | AKR1C3 (0.80) | AKR1C3GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3104370 | 0.85 | AKR1C3 (1.00) | AKR1C3GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3109604 | 0.84 | AKR1C3 (0.78) | AKR1C3MEN1KMT2ARAB9APOLB | |
| SCHEMBL3106364 | 0.84 | AKR1C3 (0.78) | AKR1C3GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3095191 | 0.84 | AKR1C3 (0.78) | AKR1C3GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3106490 | 0.84 | AKR1C3 (0.78) | AKR1C3GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3089444 | 0.84 | AKR1C3 (0.78) | AKR1C3GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13109062 | 0.84 | AKR1C3 (0.78) | AKR1C3GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL11981692 | 0.83 | AKR1C3 (0.77) | AKR1C3GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL11981693 | 0.83 | AKR1C3 (0.77) | AKR1C3GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513422-B2 | Piperidine derivative | ASTELLAS PHARMA INC. (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8513422-B2 | Piperidine derivative | ASTELLAS PHARMA INC. (JP) | 2013-08-20 | — | — | US | disclosed |
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2181990-A1 | PIPERIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | AR, NR5A1, CYP17A1 | AKR1C3 72/4885GRIN2D 1525/4885GRIN3B 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.